H.C. Wainwright lowered the firm’s price target on Immunovant (IMVT) to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company’s data readouts in 2027, with an expected potential launch in 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Strategic Developments and Financial Strength Justify Buy Rating
- Immunovant, Inc. Reports Strategic Progress and Financial Results
- Immunovant reports Q4 EPS (64c), consensus (72c)
- Immunovant sees cash runway through GD readout expected in 2027
- IMVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?